Team

Team
The SmartLigs team has extensive experience in different disciplines related to drug discovery, including biology, chemistry, pharmacology and informatics, providing us with broad technical knowledge. Our Scientific Board is composed of scientific experts from independent organizations such as Universities and governmental research institutes.
Cristina González Valdespino
Business Development Manager
Cristina obtained her degree in Biological Sciences at the University of Leon and further a Master on Clinical Trials at the Autonoma University of Madrid. She has over 7 years experience in the Biotech sector as evaluator in Suanfarma Biotech Venture Capital and then in Genoma España Foundation supporting the biotech sector arising from spanish public research institutions and acting as a link between industry and academia.
Dr. Almudena Perona
Project Manager
Dr. Perona has a PhD in Organic Chemistry from the UNED University and specialized in organic synthesis for Heterocycles and structural elucidation of simple organic molecules by NMR. She carried out post-doctoral research at Molecular Biology Center “Severo Ochoa” CSIC Madrid and was involved in several in silico drug discovery projects, through the study of interaction between proteins and small molecules, mainly by docking protein-ligand and molecular dynamics software.
Dr. Rubén Gil Redondo
Co-founder and Scientific Advisor
Dr. Gil is a Computer Engineer by Alcalá de Henares and UNED Universities and further a Master on Bioinformatics and Computational Biology at Complutense University of Madrid, he holds a PhD in Biotechnology from the Autónoma University of Madrid. He has over 10 years of experience in design and implementation of informatics technologies for several private companies (Siemens, Caser and Software AG), and a special dedication to drug discovery in the Bioinformatics Unit at Molecular Biology Center “Severo Ochoa” (CSIC-UAM). Rubén has published several scientific articles and is an author on a patent claiming new inhibitors useful in chemotherapy. After receiving business training in the Bio-entrepreneurs Campus of Genoma España, he decided to found SmartLigs and became the CEO
Dr. Antonio Morreale
Co-founder and Scientific Advisor
Dr. Morreale has a PhD degree in Organic Chemistry from Alcalá de Henares University, Madrid. He has a wide experience in the use of theoretical methods in molecular modeling and finding/design of new drugs. He is an author or co-author of nearly 50 publications and patents related to drug discovery. Currently, he is the responsible of the research group on drug design at the Bioinformatics Unit at Molecular Biology Center “Severo Ochoa” (CSIC-UAM).
David Abia Holgado
Co-founder and Scientific Advisor
David studied Biology at Complutense University of Madrid and holds a degree in Advanced Studies on Genetics from the same University. He has over 8 years’ experience in diagnosis kits development for tumor detection and for virus genotype studies on micro-arrays data base. He is also an expert on computational clusters management and proteins modeling. He is an author or co-author of several publications and patents. Now, he is the Technical Director of the Bioinformatics Service at the Molecular Biology Center “Severo Ochoa” (CSIC-UAM).
Dr. Celerino Abad-Zapatero
Scientific Advisor
Dr. Abad-Zapatero received a BSc degree in Physics from the University of Valladolid in Spain, and obtained his PhD in Biophysics (Protein Crystallography) from the University of Texas. He did postdoctoral work in virus/macromolecular crystallography at Purdue University. He was the founding member of the Protein Crystallography Lab at Abbott Laboratories and worked there for more than twenty two years in Structure-Based and Fragment-Based Drug Discovery. He is a co-author of the patent on the development of the fragment-based screening by crystallography (CRYSTALEADTM) methodology at Abbott.
He is currently Adjunct Professor at the Center for Pharmaceutical Biotechnology of the University of Illinois at Chicago, where he collaborates with groups in Europe and the USA.  His research interests are focused in developing more robust and predictive methods for structure, and fragment-based drug discovery using Ligand Efficiency Indices. He is an author or co-author of more than 70 reports in scientific journals and more than 30 articles and chapters in books.
Dr. Federico Gago
Scientific Advisor
Dr. Gago studied Pharmacy at Complutense University, Madrid, and holds a PhD from the Alcalá de Henares University. He followed post-doctoral studies at the Physical Chemistry Laboratory, Oxford University. He is currently a Full Professor in the Department of Pharmacology at the University of Alcalá, near Madrid. Dr. Gago has extensive expertise in the use of computational tools with a view to solving pharmacologically relevant problems involving small ligands and their macromolecular receptors (including proteins and nucleic acids) and has a long-standing experience in quantitative structure-activity relationships for series of analogues.
Dr. Gago has a consolidated track record of fruitful collaborations with groups from both academia and industry for the development of both new drug candidates and artificial receptors, as well as for providing insight in atomic detail about binding interactions. He is an author or co-author of over 130 reports in scientific journals and has contributed several book chapters